Gecko Biomedical, a Paris, France-based medical device company, closed an €8m (approximately $11m) Series A financing round.
The financing was co-led by Omnes Capital and CM-CIC Capital Finance, with participation from CapDecisif Management. In conjunction with the funding, Alexia Perouse of Omnes Capital and Karine Lignel of CM-CIC Capital Innovation will join Gecko’s board of directors.
The company intends to use the funds to pursue its development plan, from industrialization through regulatory development, to obtain the CE mark for its adhesive liquid film for use in vascular reconstruction, as well as advancing its development in minimally invasive settings.
Created in 2013, Gecko Biomedical is developing novel biodegradable surgical wound closure solutions.
Products include light-activated adhesive liquid films and patches, both of which improve the safety and efficiency of wound closure inside the body, and are suited for use during minimally invasive (or keyhole) surgery.
Gecko’s development is based on the relationships between the founders:
– Bernard Gilly and his iBionext Network;
– Robert Langer from the Massachusetts Institute of Technology (Cambridge, MA, USA)
– Jeff Karp from the Brigham and Women’s Hospital (Boston, MA, USA),
– Christophe Bancel, Chief Executive Officer, member of the iBionext Network,
– Jacques Marescaux from the Institute of Research Against Digestive Cancer (Strasbourg, France), an expert in the use of laparoscopy (keyhole surgery).